Origin Merchant Partners was retained by the Board and Executive Committee of Aeterna Zentaris (“Aeterna” or the “Company”) to provide a fairness opinion with respect to the Company’s license and assignment agreement with Strongbridge Biopharma LLC, regarding its primary drug, Macrilen, the first FDA-approved oral drug indicated for the diagnosis of Adult Growth Hormone Deficiency.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing new treatments, principally through out-licensing arrangements.
Strongbridge Biopharma LLC. is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.
Origin Senior Leads: Cathy Steiner, Jim Osler
